A new study by UCLA Health has discovered what researchers say is the first drug to fully reproduce the effects of physical ...

In a remarkable operation, Mille Lacs Tribal Police seized over 20 pounds of contraband near a Minnesota federal prison. This ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The combination of sintilimab and fruquintinib received conditional approval from China’s National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.